标题
Advances and challenges in hereditary cancer pharmacogenetics
作者
关键词
-
出版物
Expert Opinion on Drug Metabolism & Toxicology
Volume 13, Issue 1, Pages 73-82
出版商
Informa UK Limited
发表日期
2016-09-11
DOI
10.1080/17425255.2017.1233965
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways
- (2016) M. Doherty et al. ANNALS OF ONCOLOGY
- ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients
- (2016) Sinead Cuffe et al. Cancer Epidemiology
- Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?
- (2016) M Ingelman-Sundberg et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Translating neoadjuvant therapy into survival benefits: one size does not fit all
- (2016) Leticia De Mattos-Arruda et al. Nature Reviews Clinical Oncology
- A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions
- (2016) Catrin O. Plumpton et al. PHARMACOECONOMICS
- Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy
- (2016) Hyung Soon Park et al. Pharmacogenetics and Genomics
- Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer
- (2015) Lise Eckhoff et al. ACTA ONCOLOGICA
- Quantitative Assessment of the Association between ABC Polymorphisms and Osteosarcoma Response: a Meta-analysis
- (2015) Xu Chen et al. Asian Pacific Journal of Cancer Prevention
- Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients
- (2015) Xueqin Chen et al. Cancer Cell International
- Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non–Small-Cell Lung Cancer
- (2015) Hiroyuki Kobayashi et al. Clinical Lung Cancer
- Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
- (2015) Aurelia H. M. de Vries Schultink et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forUGT1A1and Atazanavir Prescribing
- (2015) RS Gammal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy
- (2015) Midori Ikeda et al. Drug Metabolism and Pharmacokinetics
- CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
- (2015) Meta H.M. Diekstra et al. EUROPEAN UROLOGY
- UGT1A1genotype and irinotecan therapy: general review and implementation in routine practice
- (2015) Marie-Christine Etienne-Grimaldi et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
- (2015) Barthelemy Diouf et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- OCT1 and imatinib transport in CML: is it clinically relevant?
- (2015) D B Watkins et al. LEUKEMIA
- Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients
- (2015) Y L Teo et al. PHARMACOGENOMICS JOURNAL
- Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies
- (2015) J E Megías-Vericat et al. PHARMACOGENOMICS JOURNAL
- Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia
- (2015) J Gregers et al. PHARMACOGENOMICS JOURNAL
- ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate
- (2015) Chuan-Xiang Ma et al. TUMOR BIOLOGY
- Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia
- (2015) Hana Salimizand et al. TUMOR BIOLOGY
- Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events
- (2015) Benedito A Carneiro et al. Expert Review of Hematology
- Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
- (2015) Sandrina Lambrechts et al. BMC Pharmacology & Toxicology
- Lack of Association between Polymorphisms in Genes MTHFR and MDR1 with Risk of Childhood Acute Lymphoblastic Leukemia
- (2015) Madara Kreile et al. Asian Pacific Journal of Cancer Prevention
- Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma
- (2015) Ying-Hsia Chu et al. PLoS One
- High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients
- (2015) Marc Delord et al. Oncotarget
- Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
- (2015) Jung Ran Choi et al. Cancer Research and Treatment
- Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib
- (2014) Benoit Beuselinck et al. ACTA ONCOLOGICA
- Lack of Association of the MDR1 C3435T Polymorphism with Susceptibility to Gastric Cancer and Peptic Ulcer: a Systemic Review and Meta-analysis
- (2014) Dan-Dan Wu et al. Asian Pacific Journal of Cancer Prevention
- Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel
- (2014) C. Vulsteke et al. BREAST CANCER RESEARCH AND TREATMENT
- MicroRNAs and their relevance to ABC transporters
- (2014) Sierk Haenisch et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Impact ofABCB1single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival inFLT3wild-typede novoAML patients with normal karyotype
- (2014) Ingrid Jakobsen Falk et al. BRITISH JOURNAL OF HAEMATOLOGY
- Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor
- (2014) Dong-Hoe Koo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity
- (2014) S. M. Offer et al. CANCER RESEARCH
- Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance
- (2014) Oliver Bruhn et al. Expert Opinion on Drug Metabolism & Toxicology
- Clinical impact ofABCC1andABCC2genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients
- (2014) A. Au et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia
- (2014) Jacob Vine et al. LEUKEMIA & LYMPHOMA
- Genetic variants may play an important role in mRNA–miRNA interaction
- (2014) Anneke N. Werk et al. Pharmacogenetics and Genomics
- MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis
- (2014) Bailing Zu et al. PHARMACOGENOMICS
- Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer
- (2014) Jatinder Kaur Lamba et al. PHARMACOGENOMICS
- The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis
- (2014) M M Dias et al. PHARMACOGENOMICS JOURNAL
- ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis
- (2014) Q Zheng et al. PHARMACOGENOMICS JOURNAL
- Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
- (2014) Annamaria Ruzzo et al. Scientific Reports
- Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)
- (2013) C. Vulsteke et al. ANNALS OF ONCOLOGY
- A common novel splice variant ofSLC22A1(OCT1)is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia
- (2013) Jacob Grinfeld et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
- (2013) A. T. Nies et al. CLINICAL CANCER RESEARCH
- A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity
- (2013) S M Offer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients
- (2013) Maya Koren-Michowitz et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Polymorphisms in the methotrexate transport pathway
- (2012) Elixabet Lopez-Lopez et al. Pharmacogenetics and Genomics
- A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
- (2011) E Marcuello et al. BRITISH JOURNAL OF CANCER
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
- (2011) M V Relling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
- (2011) M V Relling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells
- (2009) X. Wu et al. CANCER RESEARCH
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
- (2008) N Misaghian et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now